Published in Virchows Arch on September 07, 2013
Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch (2014) 1.00
Immunohistochemical Assessment of HER3 Expression in Odontogenic Cysts. Iran Red Crescent Med J (2015) 0.75
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications. Dis Markers (2016) 0.75
A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR. Am J Cancer Res (2017) 0.75
Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients. Wien Med Wochenschr (2015) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Lung cancer. N Engl J Med (2008) 13.49
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell (2006) 10.28
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol (2003) 8.17
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J (1997) 5.70
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
Stat proteins and oncogenesis. J Clin Invest (2002) 4.79
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol (1996) 4.47
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther (2004) 2.39
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J (1997) 2.02
Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer (2002) 1.97
The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther (2008) 1.90
Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol (2008) 1.73
Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene (2009) 1.67
Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem (2002) 1.62
The epidermal growth factor receptor family. Endocr Relat Cancer (2005) 1.55
Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res (2004) 1.32
The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res (2006) 1.20
Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med (2012) 1.11
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer (2010) 1.05
ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. Int J Cancer (2006) 1.05
The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm (Weinheim) (2008) 1.03
HER2/neu expression in malignant lung tumors. Semin Oncol (2002) 0.94
Resistance mechanisms of tumour cells to EGFR inhibitors. Clin Transl Oncol (2009) 0.89
Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology (2010) 0.87
Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis. J Clin Pathol (2003) 0.86
HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significance. J Oral Pathol Med (2009) 0.85
Nuclear translocation of HER-4/c-erbB-4 is significantly correlated with prognosis of esophageal squamous cell carcinoma. J Surg Oncol (2008) 0.84
Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res (1996) 0.83
Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. Lung Cancer (2007) 0.83
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res (2007) 0.83
Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. Ann Thorac Surg (2001) 0.83
Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J (2000) 0.82
Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC? Lung Cancer (2005) 0.79
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst (2005) 9.10
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2012) 5.16
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2004) 3.54
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst (2007) 3.25
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol (2009) 3.15
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol (2005) 2.95
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 2.95
Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist (2007) 2.15
Adrenal oncocytic neoplasm: a systematic review. Urol Int (2012) 1.99
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene (2003) 1.88
BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One (2007) 1.86
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst (2010) 1.73
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol (2012) 1.55
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol (2011) 1.47
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer (2003) 1.44
A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med (2013) 1.42
Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology. BMC Syst Biol (2015) 1.39
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst (2006) 1.38
Adenocarcinoma of the third and fourth portions of the duodenum: results of surgical treatment. Arch Surg (2003) 1.36
Surgical treatment of pancreatic head carcinoma in elderly patients. Arch Surg (2006) 1.33
Shock induced by spontaneous rupture of a giant thymoma. Ann Thorac Surg (2007) 1.24
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer (2009) 1.17
Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res (2005) 1.15
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. J Thorac Oncol (2015) 1.14
Primary breast lymphomas: a multicentric experience. World J Surg Oncol (2010) 1.13
MIB-1 Cell membrane reactivity: a finding that should be interpreted carefully. Appl Immunohistochem Mol Morphol (2008) 1.13
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol (2009) 1.13
Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol (2011) 1.12
Schwannoma of the breast: a case report and review of the literature. Tumori (2007) 1.10
Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod Pathol (2003) 1.10
Challenging problems in malignancy: case 1. Presentation of small-cell lung cancer with marked hyperamylasemia. J Clin Oncol (2004) 1.02
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer (2012) 1.02
Long glucocorticoid-induced leucine zipper (L-GILZ) protein interacts with ras protein pathway and contributes to spermatogenesis control. J Biol Chem (2011) 1.01
CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment. J Thorac Oncol (2015) 1.01
Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene. J Clin Oncol (2014) 1.01
Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica (2010) 1.00
Preoperative embolization in surgical management of giant thoracic sarcomas. Eur J Cardiothorac Surg (2007) 1.00
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer (2008) 0.99
Mesenchymal chondrosarcoma of the left coronoid process: report of a unique case with clinical, histopathologic, and immunohistochemical findings, and a review of the literature. Quintessence Int (2007) 0.98
Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Lung Cancer (2004) 0.98
Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. J Thorac Oncol (2008) 0.98
Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment. Tumori (2006) 0.97
Value of Ki67 in breast cancer: the debate is still open. Lancet Oncol (2010) 0.96
Emerging drugs for small cell lung cancer--an update. Expert Opin Emerg Drugs (2012) 0.96
Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res (2004) 0.96
Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol (2012) 0.95
Isolated cardiophrenic angle node metastasis from ovarian primary. report of two cases. J Cardiothorac Surg (2011) 0.95
A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori (2005) 0.95
Primary signet-ring cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 5 cases. Appl Immunohistochem Mol Morphol (2009) 0.94
Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. J Clin Endocrinol Metab (2014) 0.93
Ectopic prostatic tissue in the bladder. Int J Urol (2005) 0.93
CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer (2009) 0.93
Pulmonary sequestration supplied by giant aneurysmal aortic branch. Ann Thorac Surg (2010) 0.92
Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. J Mol Med (Berl) (2008) 0.92
The impact of long-term exposure to space environment on adult mammalian organisms: a study on mouse thyroid and testis. PLoS One (2012) 0.92
Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. J Thorac Oncol (2013) 0.92
Surgical treatment of neuroendocrine tumors of the lung. Eur J Cardiothorac Surg (2004) 0.91
IMP3 expression in non-small cell lung cancer. Hum Pathol (2009) 0.90
Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol (2011) 0.90
Prognostic value of low and high ankle-brachial index in hospitalized medical patients. Eur J Intern Med (2011) 0.89
[Non-recurrent inferior laryngeal nerves and sympathetic-inferior laryngeal anastomotic branches: 6 years' personal experience]. Chir Ital (2008) 0.89
Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. Cancer (2007) 0.89
Biopathologic profile of breast cancer core biopsy: is it always a valid method? Cancer Lett (2005) 0.89
A unique simultaneous occurrence of paratracheal granular cell tumor and papillary thyroid carcinoma. Int J Surg Pathol (2007) 0.88
Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res (2008) 0.87
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. Lung Cancer (2008) 0.87
Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer. Future Oncol (2013) 0.87
Peroxisome proliferator activated receptor-α/hypoxia inducible factor-1α interplay sustains carbonic anhydrase IX and apoliprotein E expression in breast cancer stem cells. PLoS One (2013) 0.86
Intramedullary spinal metastasis from ovarian cancer. Lancet Oncol (2005) 0.85
Ductal carcinoma in situ with microinvasion: clinicopathologic study and biopathologic profile. Pathol Res Pract (2006) 0.85
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients. Am J Clin Oncol (2014) 0.85